Quest Partners LLC Invests $237,000 in Dynavax Technologies Co. (NASDAQ:DVAX)

Quest Partners LLC bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 21,265 shares of the biopharmaceutical company’s stock, valued at approximately $237,000.

Several other institutional investors have also recently added to or reduced their stakes in DVAX. GAMMA Investing LLC increased its holdings in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,685 shares in the last quarter. US Bancorp DE increased its holdings in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP bought a new position in Dynavax Technologies in the 3rd quarter valued at $45,000. Nisa Investment Advisors LLC boosted its stake in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares in the last quarter. Finally, Algert Global LLC bought a new stake in shares of Dynavax Technologies during the second quarter worth $140,000. 96.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

DVAX has been the topic of several research reports. The Goldman Sachs Group reduced their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $12.66 on Wednesday. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of 97.38 and a beta of 1.34. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $15.01. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The business’s 50-day simple moving average is $11.56 and its 200 day simple moving average is $11.34.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.